New inhaled treatment tested for stubborn lung bug
NCT ID NCT06585020
Summary
This study is testing whether adding an inhaled antibiotic called ARIKAYCE® to standard oral drugs can better treat Mycobacterium xenopi lung infections. It will enroll 190 adults with this specific infection to see if the inhaled medicine helps patients clear the bacteria from their lungs faster and more effectively. The goal is to find a better-tolerated treatment that improves outcomes for this difficult infection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Amiens-Picardie
RECRUITINGAmiens, 80054, France
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.